According to recent foreign media reports, Boston Scientific (NYSE: BSX) will see a major personnel change in its cardiac rhythm management and diagnostics (CRMDx) business in 2026. Scott Olson, Senior Vice President and President of the business unit, announced on LinkedIn that he plans to retire at the end of 2025.

Scott Olson, who has worked at Boston Scientific for 27 years , will be succeeded by Angelo De Rosa in early 2026 after his retirement .
Angelo De Rosa is also a seasoned veteran of Boston Scientific, having joined in 2014 as Vice President of Marketing. In recent years, he has led the company's Watchman left atrial appendage occluder business with outstanding results.
Furthermore, it is worth noting that upon taking office, Angelo De Rosa will not only lead the CRMDx business but will also join the Boston Scientific Executive Committee. Angelo De Rosa stated that his career at Boston Scientific began with cardiac rhythm management in Europe, the Middle East, and Africa, and leading the CRMDx business feels like a complete cycle for him.
Scott Olson highly approves of his successor's abilities, stating that Angelo De Rosa's achievements, from leading the Watchman team to successfully launching multiple products to expanding global patient accessibility, are undeniable. He believes that Angelo De Rosa's values and leadership style make him the best candidate for this position.
It's worth noting that on August 4th of this year, Boston Scientific's latest generation left atrial appendage occluder—the WATCHMAN FLX Pro— was officially approved in China. According to Boston Scientific's official WeChat account, this product is the world's first coated left atrial appendage occluder , suitable for non-valvular atrial fibrillation patients with high stroke risk, and can replace oral anticoagulants to prevent stroke.
Compared to other left atrial appendage occluder products, Boston Scientific's product, in addition to being the first to use a polymer coating, also boasts two major advantages: visual marking and a new 40mm size option , providing a new treatment choice for a wider range of patients.
According to data from Yaozhi Medical Devices, nearly 20 left atrial appendage occluders are currently available in China. With the improvement of China's R&D capabilities, a number of excellent domestic products have emerged in recent years, and the domestic share of such products has reached 70.59%, while the import share has been reduced to 29.41%.
The manufacturers of these products also demonstrate that domestic medical device companies are increasing their R&D efforts, and innovative achievements are constantly emerging. Of the top 10, domestic medical device companies occupy the majority, with Lifetech Scientific and Boston Scientific both ranking first with three approved products each.
Now, with a new leader about to take office, what new brilliance will Boston Scientific's cardiac rhythm management and diagnostics business shine under the guidance of the new leader? Let's wait and see.

https://news.yaozh.com/archive/46767.html